Calendario›REGN›REGN1908

REGN1908

A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

Ensayo de REGENERON PHARMACEUTICALS, INC. en Conjuntivitis alergica.

Más ensayos de: Conjuntivitis alérgica.

Fase: Fase 3
Estado: Completado
Participantes: 64
Centros: 4
Fin del objetivo primario: may 2025

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en nov 2024.

Qué mide

Ocular itch score (At day 8 post-Conjunctival Allergen Challenge (CAC)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to reduce eye allergy signs and symptoms from cat allergy. The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Más ensayos de REGN

Ensayo	Fase	Estado	Lectura de resultados
cemiplimab	Fase 2	En marcha, sin reclutar	mar 2025 (real)
Pozelimab + Cemdisiran · NIMBLE	Fase 3	En marcha, sin reclutar	jul 2025 (real)
Garetosmab · OPTIMA	Fase 3	En marcha, sin reclutar	jul 2025 (real)
Aflibercept 8 mg · ELARA	Fase 3	En marcha, sin reclutar	ago 2025 (real)
Dupilumab · ENGAGE	Fase 2	En marcha, sin reclutar	feb 2026 (real)
Fianlimab	Fase 3	En marcha, sin reclutar	mar 2026 (real)

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06602726), actualizada en may 2026.